-
Mashup Score: 0
Two immune checkpoint inhibitors are being evaluated together in a phase 1 trial for certain patients with advanced solid tumors.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 1Penpulimab Demonstrates Activity in Solid Tumors - 1 month(s) ago
Penpulimab has demonstrated activity in a phase 1b/2 trial of patients with advanced solid tumors.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet-
Penpulimab has demonstrated activity in a phase 1b/2 trial of patients with advanced #solidTumors, according to results published in @JournalCancer. https://t.co/WgvPZSRZde
-
-
Mashup Score: 0
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Could a low-cost, easily implemented presurgical intervention save lives and improve outcomes when it comes to treating #solidtumors? For patients with early-stage #breastcancer, a new study suggests there is such an intervention that can help. https://t.co/6KxhhYZy11 https://t.co/6YGvCi2IIZ
-
-
Mashup Score: 1Wolters Kluwer Health - 10 month(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Among 57 patients with KRAS G12C-mutated #solidtumors treated with #adagrasib, the overall response rate was 35.1%, disease control rate was 86%, median duration of response was 5.3 months, and median overall survival was 14 months. https://t.co/pZL12Vh4tJ https://t.co/3IxBj5Bawe
-
-
Mashup Score: 0Next-Gen RET Inhibitor for RET-Altered Solid Tumors - 10 month(s) ago
Qing Zhou, MD – Guangdong Lung Cancer Institute Preliminary data from a phase I/II study of KL590586, a next-generation selective RET inhibitor, show promising results in patients with RET-altered solid tumors. The drug demonstrated good tolerability and substantial clinical activity, including in non-small cell lun…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 Next-Gen RET Inhibitor video https://t.co/DMzW8lBHeW for RET-Altered Solid Tumors #KL590586 #RETinhibitor #SolidTumors #CancerResearch #ASCO23 - Qing Zhou, MD https://t.co/rlPbdCXQqu
-
-
Mashup Score: 0Overcoming Challenges With Use of CAR T-Cell Therapy in Solid Tumors - 12 month(s) ago
Samer A. Srour, MD, explains the history of researching chimeric antigen receptor T-cell therapy in solid tumors.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Samer A. Srour, MD, explains the history of researching CAR T-cell therapy in #solidtumors. @MDAndersonNews https://t.co/apWHhO32tY
-
-
Mashup Score: 10Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy - 12 month(s) ago
This cohort study evaluates tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Adding to the story of #TMB, this time across a large cohort of #SolidTumors #RWE #OutcomesAnalysis - Great to collaborate with the fantastic team @TempusLabs @JPatelMD Paper now out: https://t.co/BBG5W4j8nq @JAMANetworkOpen @mtmdphd @PC3Innovation @PennPrecisMed @PennCancer https://t.co/pKYUO0zvrf
-
-
Mashup Score: 1IO102-IO103 Plus Pembrolizumab Shows Promise in Treatment-Naïve, Advanced Solid Tumors - 1 year(s) ago
An investigational immunotherapy triplet combination is showing promise for the treatment of advanced solid tumors. Recruitment for the phase 2 study continues.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of IO102 and IO103 with pembrolizumab generated responses in patients with previously untreated, unresectable, or metastatic #solidtumors. https://t.co/0c3lqHXDA6
-
-
Mashup Score: 0Phase 1 Trial of TOS-358 for PI3Kα-Mutated Tumors Begins Dosing - 1 year(s) ago
A trial of TOS-358, a first-in-class covalent PI3Kα inhibitor, for various solid tumors dosed its first patient.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The first patient in a trial of TOS-358 for patients with various #solidtumors with known PI3Kα mutations has been treated. #oncology https://t.co/eiHTfeTh64
-
-
Mashup Score: 0
David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of larotrectinib for patients with solid tumors who harbor an NTRK fusion.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
David S. Hong, MD, discusses updated findings from an analysis of 3 trials which ultimately led to the approval of #larotrectinib for patients with #solidtumors who harbor an NTRK fusion. #lcsm | @MDAndersonNews https://t.co/ovURWh1gZK
-
A combination of a novel immune checkpoint inhibitor plus Keytruda is being evaluated in a preliminary trial for certain patients with advanced #SolidTumors. Read the article here: https://t.co/mUs5kp635t